CNSY · Current Report (Form 8-K) · Filed August 4, 2026

Cerenome Inc — 8-K exhibit

pstv-ex3_1.htm

EX-3.1

Exhibit 3.1

CERTIFICATE OF AMENDMENT

OF Amended and Restated CERTIFICATE OF INCORPORATION

Plus THERAPEUTICS, INC.

Plus Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY:


	1.	The name of the Corporation is Plus Therapeutics, Inc.


	2.	On June 26, 2026, the Board of Directors of the Corporation, acting in accordance with the provisions of Sections 141 and 242 of the General Corporation Law of the State of Delaware, duly adopted a resolution approving the following amendment to the Certificate of Incorporation of the Corporation.


	3.	The consent and approval of the stockholders of the Corporation for the following amendment is not required pursuant to Section 242(d)(1) of the General Corporation Law of the State of Delaware.


	4.	Article I of the Certificate of Incorporation of the Corporation is hereby amended and restated to read in its entirety as follows:

“ARTICLE I

The name of the corporation is Cerenome, Inc. (the “Corporation”).”


	5.	This amendment to the Amended and Restated Certificate of Incorporation of the Corporation shall be effective on and as of 12:01 A.M. Eastern Time on August 3, 2026, with the Secretary of State of the State of Delaware.

IN WITNESS WHEREOF, said Corporation has caused this Certificate of Amendment to be executed this 30th day of July, 2026.

By: /s/ Marc H. Hedrick, M.D.

Marc H. Hedrick, M.D.

President and Chief Executive Officer

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer